GlassScriptPhysician profile
Francisco Belette
NPI 1669464129
$32,905.68
in general payments reported to CMS, 2019-2025
90 companies · $7,665 in 2025
The $7,665 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,887 · 2020: $2,716 · 2021: $1,827 · 2022: $4,382 · 2023: $5,069 · 2024: $7,360 · 2025: $7,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $1,017 · Long Term Medical Supply Or Device Loan: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,196.19 |
| Education | $1,016.74 |
| Long Term Medical Supply Or Device Loan | $880.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,127.48 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Janssen Biotech, INC. | $2,987.39 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Novartis Pharmaceuticals Corporation | $2,821.67 | 2019-2025 | |
| Celgene Corporation | $2,598.10 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Merck Sharp & Dohme LLC | $2,077.16 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,869.31 | 2019-2025 | |
| Astellas Pharma US INC | $1,079.24 | 2019-2025 | Xospata, Xtandi, Padcev |
| Abbvie INC. | $933.44 | 2019-2025 | Venclexta, Lupron Depot |
| E.R. Squibb & Sons, L.L.C. | $920.24 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Incyte Corporation | $901.21 | 2019-2025 | Jakafi |
| Rigel Pharmaceuticals, INC. | $717.53 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Emd Serono, INC. | $697.27 | 2019-2025 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $582.60 | 2019-2025 | |
| Daiichi Sankyo INC. | $559.32 | 2019-2025 | Enhertu, Datroway |
| Eisai INC. | $553.84 | 2019-2025 |
Show all 90 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $501.18 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $395.61 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Sumitomo Pharma America, INC. | $359.69 | 2023-2025 | Orgovyx |
| Genentech USA, INC. | $359.16 | 2019-2025 | Polivy, Itovebi, Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $346.57 | 2023-2025 | Ninlaro, Iclusig |
| Stemline Therapeutics INC. | $335.23 | 2023-2025 | Orserdu |
| Pharmaessentia USA Corporation | $333.05 | 2022-2025 | Besremi |
| Amgen INC. | $321.51 | 2019-2022 | |
| Genzyme Corporation | $317.44 | 2019-2025 | |
| Beigene USA, INC. | $289.36 | 2022-2025 | Brukinsa, Tevimbra |
| Clovis Oncology, INC. | $280.27 | 2019-2022 | |
| Sobi, INC | $279.38 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $273.79 | 2019-2025 | Odomzo, Yonsa |
| Karyopharm Therapeutics INC. | $238.14 | 2021-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $219.85 | 2022-2025 | Soliris, Ultomiris |
| Verity Pharmaceuticals INC. | $214.38 | 2021-2025 | Trelstar |
| Regeneron Healthcare Solutions, INC. | $210.70 | 2019-2025 | Libtayo, Lynozyfic |
| Seagen INC. | $194.59 | 2021-2023 | Tukysa, Padcev |
| Kite Pharma, INC. | $191.05 | 2020-2023 | Yescarta |
| Morphosys, US INC. | $186.97 | 2022-2023 | Monjuvi |
| Exelixis INC. | $179.29 | 2019-2024 | Cabometyx |
| Taiho Oncology, INC. | $168.84 | 2019-2023 | |
| Gilead Sciences, INC. | $160.33 | 2019-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.44 | 2019-2024 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $148.77 | 2019-2025 | Onivyde |
| Tempus Ai, INC | $141.59 | 2024-2025 | Xt Cdx |
| Array Biopharma INC | $130.00 | 2019-2025 | Braftovi, Lorbrena, Xalkori |
| Angiodynamics, INC. | $118.66 | 2019 | |
| Beone Medicines USA, INC. | $117.24 | 2025 | Brukinsa, Tevimbra |
| Springworks Therapeutics, INC. | $110.28 | 2024-2025 | Ogsiveo |
| Tolmar, INC. | $108.05 | 2023-2025 | Rubraca, Eligard |
| Janssen Pharmaceuticals, INC | $103.94 | 2019-2025 | Xarelto |
| Adc Therapeutics America, INC. | $100.79 | 2022-2023 | |
| Pharmaand Gmbh | $100.40 | 2024-2025 | Rubraca |
| Jazz Pharmaceuticals INC. | $99.67 | 2021-2022 | |
| Mirati Therapeutics, INC. | $95.94 | 2023-2024 | Krazati |
| Cumberland Pharmaceuticals, INC. | $95.05 | 2023-2024 | Sancuso |
| Epizyme, INC. | $93.52 | 2021-2023 | Tazverik |
| Agios Pharmaceuticals, INC. | $86.28 | 2022-2025 | Pyrukynd |
| Geron Corporation | $85.23 | 2025 | Rytelo |
| Pharmacyclics LLC, An Abbvie Company | $81.29 | 2019-2022 | |
| Novocure INC. | $79.72 | 2024-2025 | Optune Lua (Novottf-200t) |
| Blueprint Medicines Corporation | $78.14 | 2024-2025 | Ayvakit |
| Myovant Sciences INC. | $73.97 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $72.09 | 2022-2024 | Precisetumor, Myrisk |
| Fennec Pharmaceuticals, INC. | $62.26 | 2024 | Pedmark |
| Legend Biotech USA INC. | $54.43 | 2025 | Carvykti |
| Dendreon Pharmaceuticals LLC | $51.18 | 2025 | Provenge |
| Pharmacosmos Therapeutics INC. | $46.38 | 2022-2025 | Monoferric |
| Kyowa Kirin, INC. | $45.31 | 2020-2023 | Poteligeo |
| Deciphera Pharmaceuticals INC. | $38.61 | 2021-2023 | Qinlock |
| Tolmar Pharmaceuticals, INC. | $37.95 | 2022 | |
| Dova Pharmaceuticals | $37.57 | 2019 | |
| Puma Biotechnology, INC. | $36.14 | 2025 | |
| Cti Biopharma Corp. | $33.13 | 2023 | Vonjo |
| Advanced Accelerator Applications | $32.59 | 2019 | |
| Aadi Bioscience, INC. | $29.17 | 2023 | Fyarro |
| Helsinn Therapeutics (U.S.), INC. | $27.35 | 2019 | |
| Coherus Oncology, INC. | $27.21 | 2022 | |
| G1 Therapeutics, INC. | $23.90 | 2022 | |
| Tesaro, INC. | $23.57 | 2019 | |
| Adaptive Biotechnologies Corporation | $22.29 | 2025 | Clonoseq |
| Intuitive Surgical, INC. | $21.94 | 2019 | |
| Shire North American Group INC | $20.63 | 2019 | |
| Caris Mpi, INC. | $19.43 | 2025 | Mi Cancer Seek |
| Emmaus Medical, INC. | $18.48 | 2019 | |
| Foundation Medicine, INC. | $17.87 | 2019 | |
| Verastem, INC. | $17.67 | 2020 | |
| Recordati_rare_diseases_inc. | $16.50 | 2024 | Sylvant |
| Organon LLC | $16.48 | 2022 | |
| Global Blood Therapeutics, INC. | $15.58 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.50 | 2025 | Givlaari |
| Amneal Pharmaceuticals LLC | $15.47 | 2023 | Neulasta, Neupogen, Avastin |
| Teva Pharmaceuticals USA, INC. | $14.52 | 2023 | |
| Apellis Pharmaceuticals, INC. | $13.33 | 2023 | Empaveli |
Drugs and devices associated with these payments
Reblozyl $1,567Kisqali $1,288Imfinzi $946Keytruda $917Enhertu $892Lynparza $714Orgovyx $710Darzalex $634Xtandi $608Tecvayli $554Talzenna $428Ibrance $341Verzenio $339Orserdu $335Jaypirca $334Venclexta $328Lenvima $323Erleada $320Jakafi $314Besremi $312Imbruvica $286Tukysa $274Stivarga $263Yonsa $253Doptelet $244Ninlaro $243Jemperli $241Zejula $241Elrexfio $240Nubeqa $238Xofigo $238Bosulif $237Inlyta $233Rezlidhia $232Tavalisse $232Odomzo $230Calquence $225Padcev $217Pluvicto $212Brukinsa $203Opdivo $197Xospata $189Adcetris $182Rubraca $179Xpovio $179Pomalyst $176Elahere $174Trelstar $170Piqray $166Talvey $166Welireg $161Retevmo $155Libtayo $150Rybrevant $148Xt Cdx $142Gavreto $140Lupron Depot $133Lorbrena $132Bavencio $126Krazati $120Onivyde $119Ogsiveo $110Carvykti $110Eligard $108Polivy $107Tevimbra $105Iclusig $103Opdualag $98.51Yescarta $97.73Ojjaara $97.50Sancuso $95.05Soliris $92.99Ultomiris $92.83Mektovi $92.57Braftovi $92.57Xalkori $92.57Datroway $86.52Rytelo $85.23Besponsa $84.06Enjaymo $82.76Optune Lua (Novottf-200t) $79.72Ayvakit $78.14Paxlovid $72.72Vonjo $68.08Pedmark $62.26Scemblix $61.33Sarclisa $59.50Tagrisso $52.75Epkinly $51.74Provenge $51.18Cablivi $47.22Keytruda Qlex $43.79Cabometyx $43.36Akeega $37.15Nerlynx $36.14Itovebi $33.22Vyloy $31.25Fyarro $29.17Gilotrif $27.27Lonsurf $27.15
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisco Belette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.